Browsing Category
Featured Articles
Roche announces FDA approval for Venclexta plus Gazyva for people with previously untreated chronic…
Roche announced that the US Food and Drug Administration (FDA) has approved Venclexta (venetoclax) in combination with Gazyva (obinutuzumab) for the treatment of people with previously…
Read More...
Read More...
Exelixis’ Collaborator Daiichi Sankyo Launches MINNEBRO (Esaxerenone) Tablets in Japan
Exelixis, Inc. announced its partner Daiichi Sankyo Company, Limited has launched MINNEBRO (esaxerenone) tablets as a treatment for patients with hypertension in Japan. With Daiichi…
Read More...
Read More...
ElevateBio Launches to Create and Operate a Portfolio of Highly Innovative Cell and Gene Therapy…
ElevateBio announced operations to create and build a broad portfolio of cell and gene therapy companies through partnerships with leading academic researchers, medical centers and…
Read More...
Read More...
Pfizer Opens New State-Of-The-Art Biologics Clinical Manufacturing Facility In Andover,…
Pfizer Inc. announced the opening of a new 175,000 square-foot manufacturing facility in Andover, Mass. Pfizer’s Andover site houses commercial manufacturing and product development…
Read More...
Read More...
Samsung BioLogics signed CDO(Contract Development Organization) contract with GI Innovation
Samsung BioLogics and GI Innovation signed a Contract Development Organization (CDO) contract for immunochemotherapy at Samsung BioLogics headquarters on Thursday.
GI Innovation…
Read More...
Read More...
Sartorius Stedim Biotech Launches New ambr 15 Cell Culture Microbioreactor System
Sartorius Stedim Biotech (SSB) is introducing its new generation of ambr 15 cell culture automated microbioreactor system. The Generation 2 is the successor to the well-established ambr…
Read More...
Read More...
AstraZeneca starts artificial intelligence collaboration to accelerate drug discovery
AstraZeneca and BenevolentAI began a long-term collaboration to use artificial intelligence (AI) and machine learning for the discovery and development of new treatments for chronic…
Read More...
Read More...
Gilead Announces Topline Data From Phase 3 STELLAR-3 Study of Selonsertib in Bridging Fibrosis (F3)…
Gilead Sciences announced that STELLAR-3, a Phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of selonsertib, an investigational, once…
Read More...
Read More...
Lilly and Avidity Biosciences Announce Licensing and Research Collaboration
Eli Lilly and Company and Avidity Biosciences, Inc. announced a global licensing and research collaboration focused on the discovery, development and commercialization of potential new…
Read More...
Read More...
Teva Announces Launch of a Generic Version of VESIcare (solifenacin succinate) Tablets in the United…
Teva Pharmaceutical Industries Ltd. announced the launch of a generic version of VESIcare ®1 (solifenacin succinate) Tablets, 5 mg and 10 mg, in the U.S.
Solifenacin Succinate…
Read More...
Read More...
SK Biopharmaceuticals and twoXAR Sign Collaboration Agreement to Discover and Develop First-In-Class…
SK Biopharmaceuticals, a pharmaceutical company focused on disorders of central nervous system and cancer, and twoXAR, Inc., an artificial intelligence (AI)-driven biopharmaceutical…
Read More...
Read More...
MS Pharma Announces Acquisition of Genepharm
MS Pharma, a fast growing pharmaceutical company based in Jordanand operating across the Middle East, Turkey and Africa, announced that it has entered into an agreement to acquire 100%…
Read More...
Read More...
Gilead and insitro Announce Strategic Collaboration to Discover and Develop Novel Therapies for NASH
Gilead Sciences Inc. and insitro announced today that the companies have entered into a strategic collaboration to discover and develop therapies for patients with nonalcoholic…
Read More...
Read More...
Lynparza approved in EU for the treatment of germline BRCA-mutated HER2-negative advanced breast…
AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) announced the European Commission has approved Lynparza (olaparib) as a…
Read More...
Read More...
WuXi Biologics and NBE-Therapeutics Announce Comprehensive ADC Development and Manufacturing…
WuXi Biologics, a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and…
Read More...
Read More...
Concerto HealthAI Enters Precision Oncology Collaboration with Pfizer
Concerto HealthAI announced that they have entered into a collaboration with Pfizer to advance work in Precision Oncology using Concerto HealthAI’s eurekaHealthTM platform, artificial…
Read More...
Read More...
Regeneron and Alnylam Announce Broad Collaboration to Discover, Develop and Commercialize RNAi…
Regeneron Pharmaceuticals and Alnylam Pharmaceuticals announced a collaboration to discover, develop and commercialize new RNA interference (RNAi) therapeutics for a broad range of…
Read More...
Read More...
NIH begins first-in-human trial of a universal influenza vaccine candidate
The first clinical trial of an innovative universal influenza vaccine candidate is examining the vaccine’s safety and tolerability as well as its ability to induce an immune response in…
Read More...
Read More...
Sandoz resubmits biosimilar pegfilgrastim application to US FDA
Sandoz, a Novartis division and a global leader in biosimilars, today resubmission of its Biologics License Application (BLA) for a proposed biosimilar pegfilgrastim to the US Food and…
Read More...
Read More...
Novartis receives FDA approval for Mayzent (siponimod), the first oral drug to treat secondary…
Novartis announced that the US Food and Drug Administration (FDA) has approved Mayzent (siponimod) for the treatment of adults with relapsing forms of multiple sclerosis, including…
Read More...
Read More...